MetLife Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

MetLife Investment Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,610	Closed	-$82.9K	–	2959
2024 Q1	$82.9K	Hold	5,610	–	–	﹤0.01%	2620
2023 Q4	$75.2K	Hold	5,610	–	–	﹤0.01%	2718
2023 Q3	$69.2K	Hold	5,610	–	–	﹤0.01%	2767
2023 Q2	$69K	Buy	+5,610	New	+$70.2K	﹤0.01%	2852

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

MetLife Investment Management's MACK Position: Q2 2024 in Review

MetLife Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 5,610 shares — an estimated $82.9K sold.

MetLife Investment Management first reported a position in MACK in Q2 2023 and held it in 4 quarters. The position peaked at $82.9K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

MetLife Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
MetLife Investment Management sold 5,610 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $82.9K.
MetLife Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2023 and held it in 4 quarters.
MetLife Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $82.9K in Q1 2024.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.